

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

New Analogs of Acyclovir Substituted at the Side Chain

Zofia Jahnz-Wechmann^a; Jerzy Boryski^a; Kunisuke Izawa^b; Tomoyuki Onishi^b; Johan Neyts^c; Erik De Clercq^c

^a Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland ^b Aminoscience Laboratories, Ajinomoto Co. Inc., Kawasaki-ku, Kawasaki, Japan ^c Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

To cite this Article Jahnz-Wechmann, Zofia , Boryski, Jerzy , Izawa, Kunisuke , Onishi, Tomoyuki , Neyts, Johan and De Clercq, Erik(2007) 'New Analogs of Acyclovir Substituted at the Side Chain', *Nucleosides, Nucleotides and Nucleic Acids*, 26: 8, 917 – 920

To link to this Article: DOI: 10.1080/15257770701506442

URL: <http://dx.doi.org/10.1080/15257770701506442>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NEW ANALOGS OF ACYCLOVIR SUBSTITUTED AT THE SIDE CHAIN

Zofia Jahnz-Wechmann and Jerzy Boryski □ *Institute of Bioorganic Chemistry,
Polish Academy of Sciences, Poznan, Poland*

Kunisuke Izawa and Tomoyuki Onishi □ *Aminoscience Laboratories, Ajinomoto
Co. Inc., Kawasaki-ku, Kawasaki, Japan*

Johan Neyts and Erik De Clercq □ *Rega Institute for Medical Research, Katholieke
Universiteit Leuven, Leuven, Belgium*

□ *A series of novel analogs of acyclovir, substituted with an alkyl (methyl, ethyl, *n*-butyl) or phenyl group at the positions 1', 4', and/or 5', has been obtained in a direct one-pot coupling reaction of guanosine and the respective 1,3-dioxolanes. The new acyclonucleosides were essentially inactive in antiviral (HSV, VV, VSV, HBV) evaluation in vitro.*


Keywords Nucleoside analogs; acyclonucleosides; transpurination; 1,3-dioxolane

INTRODUCTION

It has been shown that 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir, **1a**),¹ a selective and potent antiviral drug, may be effectively synthesized via transpurination of guanosine (**2**).^[2,3] Thus, reaction of O2',O3',O5',N²-tetraacetylguanosine with 2-acetoxyethyl acetoxymethyl ether (2-oxabutane-1,4-diol diacetate)^[4] leads to the formation of O5',N²-diacetylacyclovir (**4a**) along with its 7-regioisomer (**5a**). More recently, the approach has been simplified considerably by applying a one-pot reaction of unprotected guanosine (**2**) and 1,3-dioxolane (**3a**) instead of 2-acetoxyethyl acetoxymethyl ether, and using acetic anhydride as a solvent and reagent.^[5] Because the 1,3-dioxolane system can be synthesized easily from a variety of 1,2-diols and aldehydes, we have adopted the latter procedure for the synthesis of novel analogs of acyclovir, substituted with an alkyl (methyl, ethyl, *n*-butyl) or phenyl group at the positions 1', 4', and/or 5' of the side chain.


In this way, the application of 2-substituted dioxolanes should lead to the formation of 1'-substituted analogs of acyclovir (Scheme 1). Indeed, the

Address correspondence to Jerzy Boryski, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, PL-61704, Poznan, Poland. E-mail: jboryski@ibch.poznan.pl



SCHEME 1 Reagents and conditions: (a) Ac_2O , *p*-TsOH, 100°C , 48 hours; (b) NH_4OH , MeOH, r.t., 24 hours.

reaction of unprotected guanosine (**2**) with 2-methyl dioxolane (**3b**), performed in acetic anhydride in the presence of *p*-toluenesulfonic acid as a catalyst, was quite similar to that of unsubstituted 1,3-dioxolane, giving the 9-isomer **4b** as the main product. However, in the case of larger substituents, the yield of 9-isomers decreased and another product appeared in the reaction mixture. Its structure was determined as 7-(2-acetoxyethyl)- N^2 -acetylguanine (**6**). The larger substituent in the position 2 of dioxolane, the higher yield of **6**. In the condensation of guanosine (**2**) with 2-phenyldioxolane compound **6** was the only reaction product. Its formation can be rationalized in the following way: in the absence of substituents, the nucleophilic attack of a heterocyclic base is directed toward C-1 of the respective oxacarbenium cation (route A in Scheme 2). However, when the center C-1 is crowded, the heterocyclic base attacks an alternative position, that is C-4 of the oxacarbenium cation (route B). This leads to the cleavage of the acyclosugar chain and to the formation of **6**, which is very stable (does not undergo the 7–9 isomerization). On the other hand, the structure of **6** may be viewed as excellent evidence that the atom N7 of guanosine is a nucleophilic center, which reacts directly with sugar cations.^[3]



SCHEME 2 Mechanism of the side-product formation in transpurination of guanosine with substituted dioxolanes.

In turn, the use of 4-substituted dioxolanes (**3c-f**) allowed us to obtain 4'-substituted analogs of acyclovir (Scheme 1): compounds (**4c-f**), together with the respective 7-regioisomers (**5c-f**). In fact, the reaction mixture was even more complicated due to the formation of 5'-substituted acyclonucleosides (**7c-f**) and the corresponding 7-isomers. This can be explained in the following way: the protonation of 4-alkyl(aryl)dioxolane may lead to the two protonated structures: HO1 (**9**) and HO3 (**10**) (Scheme 2). Therefore, the dioxolane ring can be opened in two possible ways, giving the oxacarbenium cations **11** and **12**, respectively. The cation **11** should be more stable because of an electron-donating effect of the neighbouring alkyl (aryl) group and, in fact, the formation of 4'-substituted acyclonucleosides (**4c-f**) prevails, while the 5'-substituted ones (**7c-f**) are formed as minor products (ca. 10%). Nevertheless, the synthesis of compounds **4c-f** required careful purification by chromatography and crystallization. The diacetyl 9-regioisomers **4b-f** were then deprotected to acyclovir analogs **1b-f**. However, the use of monoalkylated derivatives of 1,3-dioxolane created new asymmetric centers, and this apparently resulted in a racemic mixture of *R* and *S* acyclonucleosides. A further analog with no center of chirality, 4',4',5',5'-tetramethylacyclovir (**8**), was obtained in a similar way.

The newly synthesized compounds **1b-f** and **8** were examined for their inhibitory effect on the replication of herpes simplex virus type 1 [HSV-1 (KOS, F, McIntyre)], type 2 [HSV-2 (G, 196, Lyons)], vaccinia virus (VV), vesicular stomatitis virus (VSV), thymidine kinase-deficient HSV-1 TK⁻ (KOS ACV^r) and hepatitis B virus (HBV) in cell cultures. The compounds demonstrated low cytotoxicity (minimum cytotoxic concentration >100 μ M), but despite the improved solubility and enhanced lipophilicity, the new acyclonucleosides were essentially inactive against the viruses

tested. Only the 4'-methyl derivative (**1c**), which could be considered as a 3'-deoxy analog of ganciclovir, showed some moderate activity against HSV-1 and HSV-2 (minimum inhibitory concentration in the range of 4–20 μ M).

EXPERIMENTAL

General Procedure for Synthesis of 1', 4', and/or 5'-Alkyl(aryl) Analogs of Acyclovir (**1b–f**, **8**)

A suspension of guanosine (**2**; 2.0 mmol), an appropriate dioxolane (**3b–f** or 4',4',5',5'-tetramethyl derivative; 5.0 mmol) and p-toluenesulfonic acid monohydrate (0.2 mmol) was stirred in acetic anhydride (5 mL) at room temperature for 30 minutes, and then at 100°C for 24 hours. The reaction mixture was concentrated under reduced pressure (10–15 mm Hg) at 50°C, in order to remove acetic acid and residual acetic anhydride. The residue after evaporation was stirred at 100°C, 10 mmHg, for the next 24 hours. The products were isolated by column chromatography in a chloroform—methanol or toluene—ethanol gradient. The 4'-substituted products (**4c–f**), usually contaminated with **7c–f**, were additionally purified by rechromatography in order to get analytically pure samples. The diacetyl 9-isomers were then crystallized from toluene, except for the methyl derivatives **4b** and **4c**, which were crystallized from methanol. Yield: 18–41% (**4b–f**), 15% (diacetyl **8**), 11–24% (**5b–f**). The products **4b–f** were deacetylated with 25% aqueous ammonia in methanol (1:1 v/v) at room temperature for 24 hours, to give acyclovir analogs **1b–f** in a quantitative yield. The diacetyl derivative **8** was deprotected by using 40% methylamine in water for 4 days. All acyclonucleosides were crystallized from water, and were characterized by the ^1H and ^{13}C NMR spectra and elemental analysis.

REFERENCES

1. Schaeffer, H.J.; Beauchamp, L.; de Miranda, P.; Elion, G.B.; Bauer, D.J.; Collins P. 9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group. *Nature (London)* **1978**, 272, 583–585.
2. Boryski, J.; Golankiewicz, B. Application of the transpurination reaction to synthesis of acyclic guanosine analogues. *Nucleosides Nucleotides* **1989**, 8, 529–536.
3. Boryski, J. Regioselectivity and mechanism of transpurination reactions in the guanine nucleosides series. *J. Chem. Soc. Perkin Trans.* **1997**, 2, 649–652.
4. Rosovsky, A.; Kim, S.H.; Wick, M. Synthesis an antitumor activity of an acyclonucleoside derivative of 5-fluoruracil. *J. Med. Chem.* **1981**, 24, 1177–1181.
5. Shiragami, H.; Koguchi, Y.; Tanaka, Y.; Takamatsu, S.; Uchida, Y.; Ineyama, T.; Izawa, K. Synthesis of 9-(2-hydroxyethoxymethyl)guanine (acyclovir) from guanosine. *Nucleosides Nucleotides* **1995**, 14, 337–340.